An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of ET140203 T Cells in Pediatric Subjects with Relapsed/Refractory Hepatoblastoma (HB), Hepatocellular Neoplasm-Not Otherwise Specified (HCN-NOS), or Hepatocellular Carcinoma (HCC)

The ARYA-2 study is a Phase 1/2 study to assess the safety and tolerability of the ET140203 T cell therapy in pediatric subjects with relapsed or refractory HB, HN-NOS or HCC, as well as determine the recommended Phase 2 dose (RP2D) for future studies using ET140203 T cells. 

Sponsor

Eureka Therapeutics

Status of enrollment

Accepting new patients

Ages Eligible for Study

Children ages 1 to 21 years old.

Genders Eligible for Study

Female and Male

Disease indication

Hepatoblastoma, Liver Cancer

Principal Investigator

Arun Rangaswami, MD

Contact

Karina Wong

[email protected]

 

Additional study eligibility details can be found at UCSF Clinical Trials.